1. Scrip
  2. >>R&D
  3. >>Clinical Trials

GSK Tailors SWIFT Readout Towards Asthma Approval

 
• By Elizabeth Cairns

The twice-yearly depemokimab will soon head to the regulators, but it will need to succeed repeatedly if it is to make the £3bn peak sales GSK is hoping for.    

GSK

GSK plc has high hopes for depemokimab, having previously suggested that it could bring in peak sales of more than £3bn ($3.8bn). For that to happen the ultra-long-acting IL-5 inhibitor will have to hit in a suite of late-stage trials, but the UK group is off to a good start with the results of two asthma studies.

Key Takeaways
  • GSK’s IL-5 inhibitor depemokimab has hit in two Phase III trials in severe asthma

The twin Phase III trials SWIFT-1 and SWIFT-2, which assessed depemokimab in patients with severe asthma with type 2 inflammation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Eight Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas

New Phase II data in type 2 diabetes for Novo Nordisk’s GLP-1/amylin agonist amycretin shows significant weight loss and HbA1c-lowering potential. A Phase III trial is planned.

Kelonia Draws Attention With In Vivo CAR-T Myeloma Data

 
• By Alaric DeArment

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

More from R&D

Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas

New Phase II data in type 2 diabetes for Novo Nordisk’s GLP-1/amylin agonist amycretin shows significant weight loss and HbA1c-lowering potential. A Phase III trial is planned.

Kelonia Draws Attention With In Vivo CAR-T Myeloma Data

 
• By Alaric DeArment

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

Zai Lab Takes Lead In DLL3 Lung Cancer ADC Race

 
• By Andrew McConaghie

Having built its reputation as the ‘Gateway to China’ for global firms, Zai is going global itself, moving its potential first-in-class ADC into Phase III development.